Global Anatomic Pathology Market, By Product & Service (Instrument, Consumables, Antibodies, Others), End User (Pathology Labs, Research Institutes, Hospitals, Others), Application (Disease Diagnosis, Drug Discovery & Development, Other Applications) – Industry Trends and Forecast to 2029
Anatomic Pathology Market Analysis and Size
Digital pathology has enabled pathologists to work remotely, increasing their overall productivity and assisting them in addressing case backlogs. Over the last few years, the adoption of these technologies has increased. Increased clinical use of biomarkers allows pathologists to determine disease pathogenesis at the molecular level and further guides clinical decision-making, improving patient outcomes.
Data Bridge Market Research analyses that the anatomic pathology market was valued at 18.66 billion in 2021 is expected to reach the value of USD 31.70 billion by the year 2029, at a CAGR of 6.85% during the forecast period. The rise in the Cancer cases provides growth opportunities to the market. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Anatomic pathology is a medical specialty that requires the microscopic, macroscopic, biochemical, immunologic, and molecular examination of organs and tissues in order to diagnose disease. Surgical pathology has evolved dramatically in recent years, from an ancient examination of whole bodies (autopsy) to modern techniques required for cancer diagnosis and prognosis to guide treatment decision-making in oncology.
Anatomic Pathology Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product & Service (Instrument, Consumables, Antibodies, Others), End User (Pathology Labs, Research Institutes, Hospitals, Others), Application (Disease Diagnosis, Drug Discovery & Development, Other Applications)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Bausch Health Companies Inc. (Canada), Abbott (U.S.)
|
|
Opportunities
|
|
Anatomic Pathology Market Dynamics
Drivers
- The rise in the cases of cancer
Cancer is the world's second leading cause of death, accounting for 10 million deaths by 2020. Cancer accounts for approximately one-sixth of all deaths worldwide. In 2020, 19.3 million new cancer cases were reported, with that number expected to rise to 30.2 million by 2040. This increase in cancer incidence can be attributed to the growing geriatric population as well as the overall population.
- The increase in adoption of advanced pathology equipment
The widespread use of advanced pathology equipment such as staining systems, gross imaging, and digital microscopes is poised to significantly improve anatomic pathological practises. Digital imaging solutions outperform traditional techniques in terms of specificity and accuracy, which increases service uptake in the anatomic pathology market.
- Regulatory Compliance
Maintaining compliance with medical reforms and regulations raises the demand for these solutions.
- Government investments for healthcare interoperability
The increase in the funding by the federal government to drive the adoption of these solutions further influence the market. Additionally, the surge in healthcare expenditure, advancements in healthcare infrastructure, and high demand for expanded care delivery positively affect the anatomic pathology market.
Opportunities
In oncology drug trials, anatomic pathology products and services are used to analyse quantitative data, detect morphological structures, detect pharmacodynamics markers, and understand drug mechanisms. It also stratifies trial subjects based on tissue responses to drugs. Tissue diagnostics enable efficient trials and retrospective studies by reducing the cost and time involved in these processes.
Restraints/Challenges
The scarcity of refurbished anatomic pathology instruments is a major impediment to the market's expansion. A number of end users, primarily small and medium-sized laboratories, seek cost-effectiveness and choose refurbished systems, particularly in price-sensitive developing-country markets. Given these considerations, the demand for refurbished anatomic pathology instruments is expected to rise in the coming years, as these systems provide the same functionality as new equipment at a lower cost. This is expected to reduce revenue for companies in the market that sell branded anatomic pathology instruments.
This anatomic pathology market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anatomic pathology market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Covid-19 Impact on Anatomic Pathology Market
The COVID-19 outbreak has had an impact on every aspect of the diagnostics industry, including the anatomic pathology market, globally. Despite the availability of emergency and out-of-hours services in hospitals, patient visits to hospitals have decreased significantly in recent months. Cancer patients have emerged as one of the pandemic's most severely affected patient groups. COVID-19 has significantly impacted the number of patients who have cancer screening, diagnosis, and treatment. The increased pressure caused by the rising rate of COVID-19 hospitalisation had resulted in the re-profiling of many hospitals and departments, including oncology clinics, for treating COVID-19 patients.
Recent Development
- Hologic received FDA premarket approval (PMA) for its ThinPrep GenesisTM processor for cytology processing and specimen transfer for downstream applications in May 2021.
- PHC Holding Corporation completed the acquisition of Thermo Fisher Scientific's Anatomical Pathology business in January 2019 in order to strengthen its position in the diagnostics segment.
Global Anatomic Pathology Market Scope
The anatomic pathology market is segmented on the basis of product and services, application and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product & Service
- Instrument
- Consumables
On the basis of product and services, the anatomic pathology market is segmented into instrument and consumables. Instruments are further segmented into Tissue Processing Systems, Microtomes, Cryostats and Others. Consumables are further segmented into reagents, stains & dyes, fixatives, antibodies and others.
Application
- Disease Diagnosis
- Drug Discovery and Development
- Other Applications
On the basis of application, the anatomic pathology market is segmented into disease diagnosis, drug discovery and development and other applications
End User
- Pathology Labs
- Research Institutes
- Hospitals
- Others
On the basis of end users, the anatomic pathology market is segmented into pathology labs, research institutes, hospitals and others.
Anatomic Pathology Market Regional Analysis/Insights
The anatomic pathology market is analysed and market size insights and trends are provided by country, product and services, application and end users as referenced above.
The countries covered in the anatomic pathology market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Due to the presence of major players and supportive government initiatives pertaining to training pathological programs, North America accounted for the largest revenue share. Because of favorable reimbursement policies in the United States, the increasing implementation of tissue-diagnostic related procedures in disease screening facilitates regional market growth. The Asia Pacific market is expanding due to rising demand for advanced imaging modalities, an increase in better patient care facilities, and several pathology laboratories franchising their presence. The presence of public agencies in China, such as the Pathology Branch of the Chinese Medical Association, which is aimed at assisting pathology projects, also contributes to the APAC market's rapid growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The anatomic pathology market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for anatomic pathology market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the anatomic pathology market. The data is available for historic period 2010-2020.
Competitive Landscape and Anatomic Pathology Market Share Analysis
The anatomic pathology market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to anatomic pathology market.
Some of the major players operating in the anatomic pathology market are
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Bausch Health Companies Inc. (Canada)
- Abbott (U.S.)
SKU-